Davis R M Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 346,932 shares of the biopharmaceutical company’s stock after buying an additional 9,375 shares during the period. Davis R M Inc.’s holdings in Pfizer were worth $12,725,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in PFE. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Pfizer by 98,197.9% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,948,438,709 shares of the biopharmaceutical company’s stock valued at $71,468,732,000 after buying an additional 1,946,456,532 shares in the last quarter. Moneta Group Investment Advisors LLC grew its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer in the fourth quarter valued at $3,150,472,000. Wellington Management Group LLP grew its stake in shares of Pfizer by 9.8% in the first quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock valued at $8,932,423,000 after buying an additional 19,602,359 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Pfizer by 1,034.0% in the first quarter. Renaissance Technologies LLC now owns 12,149,955 shares of the biopharmaceutical company’s stock valued at $495,718,000 after buying an additional 11,078,514 shares in the last quarter. 68.05% of the stock is owned by institutional investors.
Pfizer Price Performance
Pfizer stock opened at $29.96 on Monday. The stock’s 50 day moving average is $31.97 and its 200 day moving average is $35.23. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. The firm has a market cap of $169.17 billion, a P/E ratio of 16.35, a P/E/G ratio of 1.91 and a beta of 0.63. Pfizer Inc. has a one year low of $28.93 and a one year high of $54.93.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 5.47%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 89.62%.
Wall Street Analysts Forecast Growth
PFE has been the subject of several research reports. BMO Capital Markets cut their price target on Pfizer from $44.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, October 16th. Jefferies Financial Group raised Pfizer from a “hold” rating to a “buy” rating and raised their price target for the company from $38.00 to $39.00 in a report on Monday, October 16th. JPMorgan Chase & Co. cut their price target on Pfizer from $36.00 to $34.00 and set a “neutral” rating for the company in a report on Monday, October 16th. Truist Financial cut their price target on Pfizer from $62.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $75.00 target price on shares of Pfizer in a report on Monday, October 2nd. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $42.50.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- What is the FTSE 100 index?
- 2 stocks that under-promised and over-delivered on their earnings
- How to Invest in Apparel Stocks
- 2 overlooked stocks that crushed earnings but traded lower
- Investing in the High PE Growth Stocks
- 3 stocks that crushed earnings estimates and still tanked
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.